Denali Therapeutics (DNLI) Stock Price, News & Analysis

Company Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $18.52 to $19.90
• 50-Day Range: $19.10 to $31.58
• 52-Week Range: $14.56 to $33.33
• Volume: 956,093 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $2.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.91
• Consensus Rating: Moderate Buy

Denali Therapeutics Stock Analysis - MarketRank™

Denali Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 129th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Denali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Denali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.71) to ($2.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Denali Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Denali Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Denali Therapeutics has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.30% of the float of Denali Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Denali Therapeutics has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Denali Therapeutics has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Denali Therapeutics does not currently pay a dividend.

Dividend Growth

Denali Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.84

Percentage of Shares Shorted

6.30% of the float of Denali Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Denali Therapeutics has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Denali Therapeutics has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.27

News Sentiment

Denali Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for Denali Therapeutics this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

5 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,576,982.00 in company stock.

Percentage Held by Insiders

Only 7.90% of the stock of Denali Therapeutics is held by insiders.

Percentage Held by Institutions

92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DNLI Stock Analysis - Frequently Asked Questions

How have DNLI shares performed this year?

Denali Therapeutics' stock was trading at $20.38 at the beginning of 2025. Since then, DNLI stock has decreased by 8.0% and is now trading at $18.74.
View the best growth stocks for 2025 here.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its earnings results on Wednesday, November, 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.03.

When did Denali Therapeutics IPO?

Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DNLI
• CUSIP: N/A
• CIK: 1714899
• Web: www.denalitherapeutics.com
• Phone: (615) 866-8548
• Fax: N/A
• Employees: 430
• Year Founded: 2015

Price Target and Rating

• Average Stock Price Target: $38.91
• High Stock Price Target: $87.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +106.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-145,220,000.00
• Net Margins: N/A
• Pretax Margin: -33,119.50%
• Return on Equity: -32.94%
• Return on Assets: -30.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.98
• Quick Ratio: 9.98

Sales & Book Value

• Annual Sales: $330.53 million
• Price / Sales: 8.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.42 per share
• Price / Book: 2.54

Miscellaneous

• Outstanding Shares: 143,922,000
• Free Float: 132,552,000
• Market Cap: $2.72 billion
• Optionable: Optionable
• Beta: 1.39